UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D 2 /D 3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters

Xenobiotica, 2021-06, Vol.51 (6), p.668-679

2021

Volltextzugriff (PDF)

Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters

Xenobiotica, 2021-06, Vol.51 (6), p.668-679

2021

Volltextzugriff (PDF)

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

Proceedings of the National Academy of Sciences - PNAS, 2007-03, Vol.104 (10), p.4106-4111

2007

Volltextzugriff (PDF)

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

Drug metabolism and disposition, 2017-10, Vol.45 (10), p.1049-1059

2017

Volltextzugriff (PDF)

Biotransformation Pathways and Metabolite Profiles of Oral [ 14 C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Drug metabolism and disposition, 2020-03, Vol.48 (3), p.217-229

2020

Volltextzugriff (PDF)

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

ACS medicinal chemistry letters, 2015-06, Vol.6 (6), p.630-634

2015

Volltextzugriff (PDF)

Evaluation of the Pharmacokinetics of Felcisetrag (TAK‐954), a 5‐HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor

Clinical pharmacology in drug development, 2022-02, Vol.11 (2), p.142-149

2022

Volltextzugriff (PDF)

Meet Our Co-Editor

Drug metabolism letters, 2016-03, Vol.10 (1), p.1-1

K. Balani, Suresh

2016

Volltextzugriff (PDF)

Evaluation of the Pharmacokinetics of Felcisetrag (TAK-954), a 5-HT 4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor

Clinical pharmacology in drug development, 2022-02, Vol.11 (2), p.142-149

2022

Volltextzugriff (PDF)

Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group

Drug metabolism and disposition, 2015-04, Vol.43 (4), p.620-630

2015

Volltextzugriff (PDF)

Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT4 Receptor Agonist

European journal of drug metabolism and pharmacokinetics, 2022-05, Vol.47 (3), p.371-386

2022

Volltextzugriff (PDF)

Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes

Drug metabolism and disposition, 2006-09, Vol.34 (9), p.1600-1605

2006

Volltextzugriff (PDF)

Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection

Current topics in medicinal chemistry, 2005-09, Vol.5 (11), p.1033-1038

2005

Volltextzugriff (PDF)

Meet Our Editorial Board Member

Current drug metabolism, 2018-01, Vol.18 (10)

Balani, Suresh

2018

Volltextzugriff (PDF)

Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction

Drug metabolism and disposition, 2007-07, Vol.35 (7), p.1203-1208

2007

Volltextzugriff (PDF)

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption

European journal of drug metabolism and pharmacokinetics, 2018-06, Vol.43 (3), p.347-354

2018

Volltextzugriff (PDF)

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

Cancer chemotherapy and pharmacology, 2013-12, Vol.72 (6), p.1255-1264

2013

Volltextzugriff (PDF)

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole

Drug metabolism and disposition, 2008-07, Vol.36 (7), p.1255-1260

2008

Volltextzugriff (PDF)

Preface

Drug metabolism letters, 2019-04, Vol.13 (1), p.2-2

Balani, Suresh

2019

Volltextzugriff (PDF)

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data

Drug metabolism and disposition, 2007-01, Vol.35 (1), p.79-85

2007

Volltextzugriff (PDF)

Meet Our Editorial Board Member

Current drug metabolism, 2015-12, Vol.16 (10), p.847-847

Balani, Suresh

2015

Volltextzugriff (PDF)

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole

Drug metabolism and disposition, 2008-07, Vol.36 (7), p.1261-1266

2008

Volltextzugriff (PDF)

Preface

Drug metabolism letters, 2018-08, Vol.12 (1), p.2-2

Balani, Suresh

2018

Volltextzugriff (PDF)

Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys

Drug metabolism and disposition, 2002-10, Vol.30 (10), p.1059-1062

2002

Volltextzugriff (PDF)

Metabolism, Excretion and Pharmacokinetics of MLN3897, a CCR1 Antagonist, in Humans

Drug metabolism letters, 2016-03, Vol.10 (1), p.22-37

2016

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(96)
Buchkapitel
(4)

Sprache

Englisch
(100)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(42)
Pharmacology & Pharmacy
(34)
Humans
(32)
Animals
(26)
Biological And Medical Sciences
(26)
Medical Sciences
(24)
Male
(23)
Pharmacology. Drug Treatments
(23)
Rats
(16)
Chemistry
(15)
Rats, Sprague-Dawley
(15)
Drug Interactions
(13)
Physical Sciences
(13)
Cytochrome P-450 Enzyme System - Metabolism
(10)
Female
(10)
Area Under Curve
(9)
Administration, Oral
(8)
Chemistry, Organic
(8)
Exact Sciences And Technology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D 2 /D 3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters

Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

Biotransformation Pathways and Metabolite Profiles of Oral [ 14 C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

Evaluation of the Pharmacokinetics of Felcisetrag (TAK‐954), a 5‐HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor

Meet Our Co-Editor

Evaluation of the Pharmacokinetics of Felcisetrag (TAK-954), a 5-HT 4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor

Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group

Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT4 Receptor Agonist

Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes

Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection

Meet Our Editorial Board Member

Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole

Preface

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data

Meet Our Editorial Board Member

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole

Preface

Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys

Metabolism, Excretion and Pharmacokinetics of MLN3897, a CCR1 Antagonist, in Humans

Suchergebnisse filtern